System and method for percutaneously administering reduced pressure treatment using a flowable manifold

Abstract

A reduced pressure delivery system for applying a reduced pressure to a tissue site includes a manifold delivery tube having a passageway and a distal end, the distal end configured to be percutaneously inserted and placed adjacent the tissue site. A flowable material is provided and is percutaneously deliverable through the manifold delivery tube to the tissue site. The flowable material is capable of filling a void adjacent the tissue site to create a manifold having a plurality of flow channels in fluid communication with the tissue site. A reduced pressure delivery tube is provided that is capable of fluid communication with the flow channels of the manifold.

1 - 14 . (canceled) 
     
     
         15 . A reduced-pressure delivery system, comprising:
 a manifold delivery tube having a passageway and configured to be percutaneously inserted and placed adjacent a tissue site;   a flowable material percutaneously deliverable through the manifold delivery tube, the flowable material capable of filling a void adjacent to the tissue site to create a manifold having a plurality of flow channels; and   a reduced-pressure delivery tube adapted to be in fluid communication with the flow channels of the manifold.   
     
     
         16 . The system of  claim 15 , further comprising a reduced-pressure source adapted to be in fluid communication with the reduced-pressure delivery tube. 
     
     
         17 . The system of  claim 15 , wherein the manifold delivery tube and the reduced-pressure delivery tube are the same tube. 
     
     
         18 . The system of  claim 15 , wherein the manifold is bioresorbable. 
     
     
         19 . The system of  claim 15 , wherein the manifold serves as a scaffold for tissue growth. 
     
     
         20 . The system of  claim 15 , wherein the manifold is adapted to foam and cure in the presence of a bodily fluid. 
     
     
         21 . The system of  claim 15 , wherein the manifold is adapted to foam and cure in the presence of a bodily temperature. 
     
     
         22 . The system of  claim 15 , wherein the manifold further comprises a bioresorbable polymer dissolved in a solvent and mixed with sodium bicarbonate and citric acid. 
     
     
         23 . The system of  claim 22 , wherein the bioresorbable polymer is one of a polylactide-co-glycolide (PLAGA) polymer and a polyethylene glycol-PLAGA copolymer. 
     
     
         24 . The system of  claim 22 , wherein the solvent is methylene chloride. 
     
     
         25 . The system of  claim 15 , wherein the flowable material is chosen from the group of a liquid, a slurry, a suspension, a viscous gel, a paste, a putty, and particulate solids. 
     
     
         26 . The system of  claim 15 , wherein:
 the flowable material undergoes a phase change in the presence of at least one of a bodily fluid and a bodily temperature; and   the flowable material includes a poragen that dissolves following curing of the flowable material, the dissolution of the poragen creating the plurality of flow channels.   
     
     
         27 . The system of  claim 15 , wherein the flowable material includes microspheres having a coating that is capable of being selectively cross-linked following delivery of the flowable material to the tissue site. 
     
     
         28 . The system of  claim 27 , wherein the coating is selectively cross-linked in response to at least one of heat, light, and a chemical. 
     
     
         29 . The system of  claim 27 , wherein the microspheres following cross-linking create the plurality of flow channels. 
     
     
         30 . The system of  claim 15 , wherein:
 the flowable material is chosen from the group of a paste and a putty having an initial viscosity;   the viscosity of the flowable material decreases below the initial viscosity in the presence of shear forces during delivery to the tissue site; and   the viscosity of the flowable material reverts to the initial viscosity following delivery of the flowable material to the tissue site.   
     
     
         31 . A system for treating a tissue site, comprising:
 a delivery tube adapted to be inserted percutaneously in the tissue site; and   a flowable material adapted to be delivered through the delivery tube to form a manifold at the tissue site;   wherein the flowable material undergoes a phase change in the presence of at least one of a bodily fluid and a bodily temperature.   
     
     
         32 . A system for treating a tissue site, comprising:
 a delivery tube configured to be percutaneously inserted in the tissue site; and   a flowable bioresorbable material comprising a gel or gel-forming solution and a gas-forming porogen.   
     
     
         33 . The system of  claim 32 , wherein the gas-forming porogen is a mixture of an acid and a carbonate salt. 
     
     
         34 . The system of  claim 33 , wherein the acid is citric acid. 
     
     
         35 . The system of  claim 33 , wherein the carbonate salt is ammonium bicarbonate, sodium bicarbonate, or calcium carbonate. 
     
     
         36 . The system of  claim 32 , wherein the gel or gel-forming solution comprises collagen, gelatin, hyaluronic acid, or combinations thereof. 
     
     
         37 . The system of  claim 32 , further comprising a non-gas forming porogen. 
     
     
         38 . The system of  claim 32 , wherein the flowable bioresorbable material further comprises a microspheres or fibers. 
     
     
         39 . The system of  claim 32 , wherein the flowable bioresorbable material further comprises a compound adapted to add stiffness to the dressing. 
     
     
         40 . The system of  claim 39 , wherein the compound is calcium sulfate hemihydrate. 
     
     
         41 . The system of  claim 32 , wherein the flowable bioresorbable material further comprises a bioactive agent. 
     
     
         42 . The system of  claim 41 , wherein the bioactive agent is an antibiotic. 
     
     
         43 . The system of  claim 41 , wherein the bioactive agent is a growth factor. 
     
     
         44 . The system of  claim 32 , wherein the flowable bioresorbable material further comprises a mammalian cell.